Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM28 Monotherapy in R/R CD123+ AML
NCT05817058Phase 1Terminated
- Sponsor
- Affimed
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AFM28 in acute myeloid leukemia (AML), sponsored by Affimed. Primary endpoint: Incidence of Dose Limiting Toxicities at 28 days. Started Mar 2023; status: terminated.
02
Drugs
AFM28
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05817058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817058.